fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ASCO Highlights

Written by | 20 Aug 2018

June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.

EHA 2018: OPTIMISMM

Written by | 24 Jun 2018

Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: The Issue of Frailty in MM

Written by | 24 Jun 2018

When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

BSH 2018: Hodgkin lymphoma: tackling treatment challenges in the older patient

Written by | 21 Jun 2018

Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.

BSH 2018: Molecular biology to drive rational drug usage

Written by | 20 Jun 2018

Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.

BSH 2018 Highlights

Written by | 20 Jun 2018

In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.

Updated findings from the German Hodgkin Study Group HD18 trial

Written by | 20 Jun 2018

BEACOPP treatment offers considerable advantages in terms of overall survival and low dose regimens offer short, safe and effective treatment for newly-diagnosed advanced-stage HL patients …… 

BSH 2018: Debate: CAR-T cell therapy will become the standard of care for relapsed high-grade B-cell lymphoma within 5 years

Written by | 11 May 2018

Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.

BSH 2018: Access to new agents

Written by | 11 May 2018

Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.

BSH 2018: Personalised cancer vaccines and cellular therapy: changing the treatment paradigm for haematological malignancies

Written by | 11 May 2018

Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.